Omeprazole for acid-related disease

Efficacy with safety?

Colin Howden, R. E. Powers, S. Holt

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A degree of caution is both necessary and desirable when assessing the safety profile of any new drug. In comparative clinical trials, the reporting of adverse events by patients given omeprazole has been of the same order as for the H2RA. With the exception of a few anecdotal case reports, omeprazole has so far been shown to be safe in short- and medium-term use, with a safety profile similar to that reported with H2RA. Long-term follow-up of patients with severe gastro-oesophageal reflux disease or Zollinger-Ellison syndrome, some of whom have been receiving continuous treatment with high-dose omeprazole, is continuing. To date, no serious adverse effects have been detected.

Original languageEnglish (US)
Pages (from-to)25-30
Number of pages6
JournalJournal of Pharmaceutical Medicine
Volume2
Issue number1
StatePublished - 1992
Externally publishedYes

Fingerprint

Omeprazole
Safety
Esophageal Diseases
Zollinger-Ellison Syndrome
Gastroesophageal Reflux
Clinical Trials
Pharmaceutical Preparations
omeprazole acid
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Omeprazole for acid-related disease : Efficacy with safety? / Howden, Colin; Powers, R. E.; Holt, S.

In: Journal of Pharmaceutical Medicine, Vol. 2, No. 1, 1992, p. 25-30.

Research output: Contribution to journalArticle

@article{6aeeef56bd9e43c4953b84c12972ff94,
title = "Omeprazole for acid-related disease: Efficacy with safety?",
abstract = "A degree of caution is both necessary and desirable when assessing the safety profile of any new drug. In comparative clinical trials, the reporting of adverse events by patients given omeprazole has been of the same order as for the H2RA. With the exception of a few anecdotal case reports, omeprazole has so far been shown to be safe in short- and medium-term use, with a safety profile similar to that reported with H2RA. Long-term follow-up of patients with severe gastro-oesophageal reflux disease or Zollinger-Ellison syndrome, some of whom have been receiving continuous treatment with high-dose omeprazole, is continuing. To date, no serious adverse effects have been detected.",
author = "Colin Howden and Powers, {R. E.} and S. Holt",
year = "1992",
language = "English (US)",
volume = "2",
pages = "25--30",
journal = "Pharmaceutical Medicine",
issn = "1178-2595",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Omeprazole for acid-related disease

T2 - Efficacy with safety?

AU - Howden, Colin

AU - Powers, R. E.

AU - Holt, S.

PY - 1992

Y1 - 1992

N2 - A degree of caution is both necessary and desirable when assessing the safety profile of any new drug. In comparative clinical trials, the reporting of adverse events by patients given omeprazole has been of the same order as for the H2RA. With the exception of a few anecdotal case reports, omeprazole has so far been shown to be safe in short- and medium-term use, with a safety profile similar to that reported with H2RA. Long-term follow-up of patients with severe gastro-oesophageal reflux disease or Zollinger-Ellison syndrome, some of whom have been receiving continuous treatment with high-dose omeprazole, is continuing. To date, no serious adverse effects have been detected.

AB - A degree of caution is both necessary and desirable when assessing the safety profile of any new drug. In comparative clinical trials, the reporting of adverse events by patients given omeprazole has been of the same order as for the H2RA. With the exception of a few anecdotal case reports, omeprazole has so far been shown to be safe in short- and medium-term use, with a safety profile similar to that reported with H2RA. Long-term follow-up of patients with severe gastro-oesophageal reflux disease or Zollinger-Ellison syndrome, some of whom have been receiving continuous treatment with high-dose omeprazole, is continuing. To date, no serious adverse effects have been detected.

UR - http://www.scopus.com/inward/record.url?scp=0026570327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026570327&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 25

EP - 30

JO - Pharmaceutical Medicine

JF - Pharmaceutical Medicine

SN - 1178-2595

IS - 1

ER -